Pfizer

Drugmaker Pfizer Ltd on Tuesday reported a 65.72 per cent increase in net profit to Rs 313.25 crore in the September quarter, driven by gains from exceptional items. The company had posted a profit of Rs 189 crore in the corresponding period of the previous fiscal year, Pfizer said in a regulatory filing. Pfizer has accounted for exceptional gains of Rs 132.06 crore in the September quarter from its parent entity Pfizer Inc USA following the sale of Minipress XL. Consequent to the decision, Pfizer Ltd discontinued the manufacture of Minipress XL from September 7, 2026, according to the filing. Its profit before tax and exceptional items stood at Rs 290.77 crore during the quarter under review, up 13.86 per cent year-on-year. It was at Rs 255.37 crore in the corresponding quarter of the previous fiscal year. Its total income rose to Rs 774.19 crore during the quarter under review from Rs 684.19 crore in the year-ago period. Pfizer reported an increase in total expenses to Rs 483.2

Pfizer on Tuesday said patient safety and product quality are its highest priorities, reacting to the Karnataka Food and Drug Administration's (FDA) action regarding the circulation of counterfeit drugs. The Karnataka health regulator on Sunday said it has cancelled 16 drug licences of retailers and wholesalers and suspended eight others in connection with the alleged distribution and sale of spurious medicines. "Patient safety and product quality are of the highest priority for us at Pfizer," the company said in a statement late on Tuesday evening. Pfizer claimed that it has been working with authorities for the last one month since the matter was brought to its attention. "Since then, we have taken several actions to support the investigation, including removing from the market Pfizer batches (where batch numbers were copied by counterfeit) to avoid confusion, supporting to differentiate between original and counterfeit product, and providing technical and other relevant informat

Pfizer agreed to share a portion of its net increased revenue from charging higher prices abroad with US Department of Health and Human Services

The company's board approved the transaction on Monday, following which Novartis India executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc and Pfizer Products Inc

Novartis India Ltd on Monday announced that its Board of Directors has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA for a total consideration of approximately Rs 1,250 crore. In a regulatory filing, the company said the transaction involves the acquisition of the trademarks registered in India and certain related intellectual property rights for a total aggregate consideration of Rs 1,250 crore. The company has executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc USA and Pfizer Products Inc USA, with the signing and closing of the transaction scheduled to occur simultaneously, as per the filing. The company noted that Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH). The filing further highlighted that as per IQVIA MAT July 2026 data, Minipre

Revenue from operations increased 8.3 per cent to ₹653.17 crore, while total expenses rose 2.6 per cent to ₹421.33 crore in the June quarter on a year-on-year basis

Q1FY27 company results: Firms including Ambuja Cements, Suzlon Energy, Birlasoft, Tata Capital, Cholamandalam Investment and Finance, and Pine Labs are also to release their April-June earnings today

Q4FY26 company results: Firms including Berger Paints, Torrent Power, Max Financial Services, Nazara Technologies, and Vinati Organics are also to release their January-March earnings today

In the December quarter, Pfizer reported an 11 per cent rise in consolidated net profit to ₹1,41.84 crore, compared to ₹127.6 crore a year ago

Q3FY26 company results: Firms including GlaxoSmithKline Pharmaceuticals, The Ramco Cements, Linde India, Gulf Oil Lubricants, and Bata India are also to release their October-December earnings today

More than 50% of Nifty Smallcap 250 stocks are seen trading with a 'Death Cross' pattern, show technical charts; 15 smallcaps witnessed this bearish chart formation in New Year 2026.

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk

Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the inclusion of these drugs may ease the burden on state medical insurance

Pfizer has introduced Rimegepant ODT for adults who do not respond well to triptans, entering a migraine market nearing $200 million, projected to double by 2030 as India faces rising disease burden

The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Pfizer has pledged to make some medicines available at lower prices for the Medicaid programme and in return gained relief from immediate import tariffs

Pfizer and the White House were deadlocked for months over lowering US drug prices, with Trump demanding quick results from drug executives right from the start of his second term

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.